🇺🇸 Carboplatin + Gemcitabine in United States

95 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Disease Progression — 16 reports (16.84%)
  2. Inappropriate Schedule Of Product Administration — 12 reports (12.63%)
  3. Fatigue — 11 reports (11.58%)
  4. Weight Decreased — 9 reports (9.47%)
  5. Weight Fluctuation — 9 reports (9.47%)
  6. Neutropenia — 8 reports (8.42%)
  7. Neutrophil Count Abnormal — 8 reports (8.42%)
  8. Weight Increased — 8 reports (8.42%)
  9. Diarrhoea — 7 reports (7.37%)
  10. Malignant Neoplasm Progression — 7 reports (7.37%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Carboplatin + Gemcitabine approved in United States?

Carboplatin + Gemcitabine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Carboplatin + Gemcitabine in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.